Drugs / ERZOTABART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04824794 | Mar 2021 → Jun 2025 | acute myeloid leukemia, diffuse large B-cell lymphoma, refractory plasma cell neoplasm | Genmab | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERZOTABART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315021 ↗ |
| Known as | GEN3014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04824794 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315021 ↗ |
| Route | Intravenous | “GEN3014 is administered by IV infusion.” NCT04824794 ↗ |